Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481258 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02481258: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT02481258 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02481258, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary objective of the current study is to determine whether Ataciguat (HMR1766) slows progression of valve calcification in patients with moderate calcific aortic valve stenosis. Secondary and tertiary objectives are to determine whether Ataciguat slows progression of aortic valve function, reduces systemic inflammation, and prevents left ventricular dysfunction in patients with moderate calcific aortic valve stenosis.
Interventions
- DRUG Ataciguat (HMR1766)
- OTHER Placebo Comparator: Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02481258
The ClinicalTrials.gov registry entry for NCT02481258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ataciguat (HMR1766) is the first listed.
NCT02481258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02481258 about?
NCT02481258 is a clinical study titled "A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification". The primary objective of the current study is to determine whether Ataciguat (HMR1766) slows progression of valve calcification in patients with moderate calcific aortic valve stenosis. Secondary and tertiary objectives are to determine whether Ataciguat slows progression of aortic valve function, r...
What is the current status of trial NCT02481258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2015-06. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT02481258?
The interventions under investigation include: Ataciguat (HMR1766) (DRUG), Placebo Comparator: Matching Placebo (OTHER).
Who is sponsoring clinical trial NCT02481258?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.